Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2007 1
2009 1
2010 1
2011 1
2012 1
2014 3
2015 4
2016 2
2018 2
2019 1
2020 3
2021 1
2022 6
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Impact of web application support versus standard management on adherence with adjuvant hormone therapy in patients treated for breast cancer: the WEBAPPAC study.
Gernier F, Grellard JM, Dupont C, Castel H, Fernette M, Lahaye F, Charles RM, Leroux T, Ory C, Faveyrial A, Morel A, Emile G, Levy C, Segura C, Allouache D, Johnson A, Geffrelot J, Gunzer K, Lelaidier A, Girault G, Dubot-Poitelon C, San C, Lequesne J, Clarisse B. Gernier F, et al. Among authors: allouache d. BMC Cancer. 2023 Aug 9;23(1):736. doi: 10.1186/s12885-023-11242-1. BMC Cancer. 2023. PMID: 37559004 Free PMC article. Clinical Trial.
Sleep macro- and microstructure in breast cancer survivors.
Perrier J, Duivon M, Clochon P, Rehel S, Doidy F, Grellard JM, Segura-Djezzar C, Geffrelot J, Emile G, Allouache D, Levy C, Polvent S, Viader F, Eustache F, Joly F, Giffard B. Perrier J, et al. Among authors: allouache d. Sci Rep. 2022 Feb 15;12(1):2557. doi: 10.1038/s41598-022-06664-z. Sci Rep. 2022. PMID: 35169245 Free PMC article.
Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.
Bachelot T, Cottu P, Chabaud S, Dalenc F, Allouache D, Delaloge S, Jacquin JP, Grenier J, Venat Bouvet L, Jegannathen A, Campone M, Del Piano F, Debled M, Hardy-Bessard AC, Giacchetti S, Mouret-Reynier MA, Barthelemy P, Kaluzinski L, Mailliez A, Legouffe E, Sephton M, Bliss J, Canon JL, Penault-Llorca F, Lemonnier J, Cameron D, Andre F. Bachelot T, et al. Among authors: allouache d. J Clin Oncol. 2022 Nov 10;40(32):3699-3708. doi: 10.1200/JCO.21.02179. Epub 2022 May 23. J Clin Oncol. 2022. PMID: 35605174 Clinical Trial.
HELENA: HER2-Low as a prEdictive factor of response to Neoadjuvant chemotherapy in eArly breast cancer.
Cherifi F, Da Silva A, Johnson A, Blanc-Fournier C, Abramovici O, Broyelle A, Levy C, Allouache D, Hrab I, Segura C, Morel A, Villemin M, Boscher C, Dubot-Poitelon C, Rottier P, Lequesne J, Emile G. Cherifi F, et al. Among authors: allouache d. BMC Cancer. 2022 Oct 20;22(1):1081. doi: 10.1186/s12885-022-10163-9. BMC Cancer. 2022. PMID: 36266623 Free PMC article.
Cognitive Changes After Adjuvant Treatment in Older Adults with Early-Stage Breast Cancer.
Lange M, Heutte N, Noal S, Rigal O, Kurtz JE, Lévy C, Allouache D, Rieux C, Lefel J, Clarisse B, Leconte A, Veyret C, Barthélémy P, Longato N, Tron L, Castel H, Eustache F, Giffard B, Joly F. Lange M, et al. Among authors: allouache d. Oncologist. 2019 Jan;24(1):62-68. doi: 10.1634/theoncologist.2017-0570. Epub 2018 Jun 22. Oncologist. 2019. PMID: 29934409 Free PMC article.
Pretreatment neutrophil to lymphocyte ratio as prognostic factor in metastatic breast cancer treated with cyclin dependent kinase 4/6 inhibitors.
Rottier P, Emile G, Johnson A, Levy C, Allouache D, Hrab I, Segura C, Morel A, Villemin M, Dubot-Poitelon C, Boismoreau L, Cherifi F, Lequesne J, Da Silva A. Rottier P, et al. Among authors: allouache d. Front Oncol. 2023 Jan 19;12:1105587. doi: 10.3389/fonc.2022.1105587. eCollection 2022. Front Oncol. 2023. PMID: 36741710 Free PMC article.
25 results